American Heart Journal
Volume 150, Issue 4 , Pages 689.e1-689.e9 , October 2005

Determinants of coronary events in patients with stable angina: Results from the Impact of Nicorandil in Angina Study

  • The IONA Study Group

      Affiliations

    • Corresponding Author InformationReprint requests: Alex D. McMahon, Robertson Centre for Biostatistics, University of Glasgow, G12 8QQ Glasgow, Scotland, UK. E-mail: alexm@stats.gla.ac.uk

Received 8 December 2004 ,Accepted 27 March 2005.

References 

  1. Tunstall-Pedoe H. Angina pectoris: epidemiology and risk factors. Eur Heart J. 1985;6:1–5
  2. Gandhi MM. Clinical epidemiology of coronary heart disease in the UK. Br J Hosp Med. 1997;58:23–27
  3. Hemingway H, Shipley M, Britton A, et al. Prognosis of angina with and without a diagnosis: 11 year follow up in the Whitehall II prospective cohort study. BMJ. 2003;327:895
  4. Stewart S, Murphy N, Walker A, et al. The current cost of angina pectoris to the National Health Service in the UK. Heart. 2003;89:848–853
  5. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1995;308:81–106
  6. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  8. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  9. Rubins HB, Sander JR, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  10. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359:1269–1275
  11. The IONA Study Group. Impact Of Nicorandil in Angina (IONA):design, methodology and management. Heart. 2003;85:E9
  12. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol. 2002;18:371–379
  13. Cox J, Naylor CD. The Canadian Cardiovascular Society grading scale for angina pectoris: is it time for refinements?. Ann Intern Med. 1992;117:677–683
  14. Dagenais GR, Armstrong PW, Theroux P, et al. Revisiting the Canadian Cardiovascular Society grading of stable angina pectoris after a quarter of a century of use. Can J Cardiol. 2002;18:941–944
  15. Lampe FC, Whincup PH, Shaper AG, et al. Variability of angina symptoms and the risk of major ischemic heart disease events. Am J Epidemiol. 2001;153:1173–1182
  16. Brand FN, Larson M, Friedman LM, et al. Epidemiologic assessment of angina before and after myocardial infarction: the Framingham study. Am Heart J. 1996;132:174–178
  17. Herlitz J, Karlson BW, Richter A, et al. Occurrence of angina pectoris prior to acute myocardial infarction and its relation to prognosis. Eur Heart J. 1993;14:484–491
  18. Lampe FC, Whincup PH, Wannamethee SG, et al. Chest pain on questionnaire and prediction of major ischaemic heart disease events in men. Eur Heart J. 1998;19:63–73
  19. Rizik DG, Healy S, Margulis A, et al. A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol. 1995;75:993–997
  20. Van Miltenburg A, Van Zijl AJ, Simoons ML, et al. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol. 1995;25:1286–1292
  21. Drozdz J, Krzeminzska-Pakula M, Chrzanowski L, et al. Predictors of long term outcome in medically treated patients with unstable angina. Can J Cardiol. 2003;19:135–139
  22. Tanne D, Shotan A, Goldbourt U, et al. Severity of angina pectoris and risk of ischemic stroke. Stroke. 2003;33:245–250
  23. McMahon AD. Observation and experiment with the efficacy of drugs: a warning example using a cohort of NSAID and ulcer healing drug users. Am J Epidemiol. 2001;154:557–562
  24. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf. 2003;12:551–558
  25. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using databases from two large-scale postinfarction studies. Am Heart J. 1999;138:577–585
  26. Teo KK, Catellier DJ. Long-term nitrate use in chronic coronary artery disease: need for a randomized controlled trial. Am Heart J. 1999;138:400–402
  27. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test?. BMJ. 1999;319:1562–1565
  28. Seres L, Valle V, Marrugat J, et al. Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. Am J Cardiol. 1999;84:963–969

PII: S0002-8703(05)00339-X

doi: 10.1016/j.ahj.2005.03.040

American Heart Journal
Volume 150, Issue 4 , Pages 689.e1-689.e9 , October 2005

Article Tools

* Image Usage & Resolution